Yahoo Finance CureVac First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag
CureVac (NASDAQ:CVAC) First Quarter 2023 Results
Key Financial Results
Revenue: €7.13m (down 71% from 1Q 2022).
Net loss: €57.4m (loss widened by 280% from 1Q 2022).
€0.27 loss per share (further deteriorated from €0.081 loss in 1Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CureVac EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 43%. Earnings per share (EPS) exceeded analyst estimates by 29%.
Looking ahead, revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 1.7% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for CureVac that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
